Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties
- 31 March 2026
- journal article
- review article
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 24 (6) , 1228-1237
Abstract
Objective: The objective of this review will be to appraise the measurement properties of patient-reported outcome assessment tools for lung cancer. Introduction: Patients with lung cancer manifest varying degrees of physical and psychosocial symptoms attributable to disease pathology and treatment-related complications, which significantly impair their quality of life. Although a few patient-reported outcome assessment tools are available for lung cancer, a comprehensive and standardized comparative analysis of their measurement properties is notably lacking. Eligibility criteria: Eligible studies will include patients aged ≥18 years who are diagnosed with lung cancer at any disease stage (I–IV), regardless of treatment modality (eg, surgery, pharmacotherapy, chemotherapy, radiotherapy, neoadjuvant therapy, palliative care). Empirical studies that examine the development or validation of patient-reported outcome measures for patients with lung cancer will be considered if they evaluate at least 1 measurement property (eg, reliability, validity, responsiveness). Methods: The following databases will be searched: PubMed, Web of Science Core Collection, CINAHL (EBSCOhost), Cochrane Library, Embase (Ovid), PsycINFO (Ovid), CNKI, Wanfang, SINOMED, and Weipu. To minimize publication bias and identify unpublished studies, gray literature sources will also be explored, including unpublished agency reports, professional organization websites, and dissertation/thesis databases. Two reviewers will independently conduct study selection and data extraction. Methodological quality appraisal, synthesis of the quality of PROMs, and evidence quality grading will be conducted by 2 reviewers in strict accordance with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology. Review registration: PROSPERO CRD420251028373Keywords
This publication has 25 references indexed in Scilit:
- Network analysis of core symptom changes in lung cancer survivors: a longitudinal studyJournal of Cancer Survivorship, 2025
- COSMIN reporting guideline for studies on measurement properties of patient‑reported outcome measures: version 2.0Quality of Life Research, 2025
- Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024Quality of Life Research, 2024
- The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice GuidelineAnnals of Oncology, 2022
- Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung CancerJAMA, 2019
- COSMIN guideline for systematic reviews of patient-reported outcome measuresQuality of Life Research, 2018
- COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome MeasuresQuality of Life Research, 2017
- PRESS Peer Review of Electronic Search Strategies: 2015 Guideline StatementJournal of Clinical Epidemiology, 2016
- Meta-analysis in clinical trials revisitedContemporary Clinical Trials, 2015
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentLung Cancer, 1995